LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

With the wide clinical use of the third‐generation epidermal growth factor receptor (EGFR) inhibitor osimertinib for the treatment of EGFR‐mutated non–small cell lung cancer (NSCLC), acquired resistance caused by EGFR C797S tertiary mutation has become a concern. Therefore, fourth‐generation EGFR in...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yingqiang, Lai, Mengzhen, Li, Shan, Wang, Yanan, Feng, Fang, Zhang, Tao, Tong, Linjiang, Zhang, Mengge, Chen, Hao, Chen, Yi, Song, Peiran, Li, Yan, Bai, Gang, Ning, Yi, Tang, Haotian, Fang, Yan, Lu, Xiaoyun, Geng, Meiyu, Ding, Ke, Yu, Ker, Xie, Hua, Ding, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819286/
https://www.ncbi.nlm.nih.gov/pubmed/34855271
http://dx.doi.org/10.1111/cas.15229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819286/
https://www.ncbi.nlm.nih.gov/pubmed/34855271
http://dx.doi.org/10.1111/cas.15229

Ejemplares similares